Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AA HMG CoA reductase inhibitors
C10AA08 Pitavastatin
D01862 Pitavastatin calcium (JAN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Dyslipidemics, HMG CoA Reductase Inhibitors
Pitavastatin
D01862 Pitavastatin calcium (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
218 Hyperlipidemia agents
2189 Others
D01862 Pitavastatin calcium (JAN)
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01660 HMG-CoA reductase inhibitor
DG01838 Pitavastatin
D01862 Pitavastatin calcium
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01838 Pitavastatin
D01862 Pitavastatin calcium
Drug classes [BR:br08332]
Cardiovascular agent
DG01946 Hypolipidemic agent
D01862 Pitavastatin calcium
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
HMGCR
D01862 Pitavastatin calcium (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01862
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01862
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01862
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01862
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01660 HMG-CoA reductase inhibitor
DG01838 Pitavastatin
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01838 Pitavastatin